糖皮质激素增敏药物的研究进展
Research Progress on Glucocorticoid-Sensitizing Drugs
DOI: 10.12677/acm.2026.1651955, PDF,    科研立项经费支持
作者: 张子诺：河北省人民医院耳鼻咽喉科，河北 石家庄；华北理工大学研究生学院，河北 唐山；黄则雷, 屈永涛, 郭明丽*：河北省人民医院耳鼻咽喉科，河北 石家庄
关键词: 糖皮质激素；糖皮质激素抵抗；药物增敏；Glucocorticoids； Glucocorticoid Resistance； Drug Sensitization
摘要: 糖皮质激素(Glucocorticoid, GC)主要通过抗炎作用和免疫抑制功能发挥临床效能，临床应用中还发现激素抵抗现象，这极大地限制了GC在临床上的应用。因此，近年来研究重点不仅聚焦于开发更强效的GC，也在关注寻找能够“增敏”机体对GC反应性的药物，以实现低剂量、高效率、高安全性的治疗目标，即增强GC在靶组织疗效的同时减少其不良反应。
Abstract: Glucocorticoids (GC) exert their clinical efficacy primarily through anti-inflammatory and immunosuppressive effects. However, clinical practice has also revealed the phenomenon of glucocorticoid resistance, which significantly limits the application of GC in clinical settings. Consequently, recent research has focused not only on developing more potent GC but also on identifying drugs that can “sensitize” the body’s responsiveness to GC, aiming to achieve therapeutic goals of low dosage, high efficiency, and high safety—that is, enhancing the efficacy of GC in target tissues while reducing their adverse effects.
文章引用：张子诺, 黄则雷, 屈永涛, 郭明丽. 糖皮质激素增敏药物的研究进展[J]. 临床医学进展, 2026, 16(5): 1533-1541. https://doi.org/10.12677/acm.2026.1651955

参考文献

[1] Nicolaides, N.C., Charmandari, E., Kino, T. and Chrousos, G.P. (2017) Stress-Related and Circadian Secretion and Target Tissue Actions of Glucocorticoids: Impact on Health. Frontiers in Endocrinology, 8, Article ID: 70. [Google Scholar] [CrossRef] [PubMed]
[2] Schwartz, H.J., Lowell, F.C. and Melby, J.C. (1968) Steroid Resistance in Bronchial Asthma. Annals of Internal Medicine, 69, 493-499. [Google Scholar] [CrossRef] [PubMed]
[3] Juliano, R.L. and Ling, V. (1976) A Surface Glycoprotein Modulating Drug Permeability in Chinese Hamster Ovary Cell Mutants. Biochimica et Biophysica Acta (BBA)-Biomembranes, 455, 152-162. [Google Scholar] [CrossRef] [PubMed]
[4] Kodan, A., Futamata, R., Kimura, Y., Kioka, N., Nakatsu, T., Kato, H., et al. (2021) ABCB1/MDR1/P‐gp Employs an ATP‐Dependent Twist‐and‐Squeeze Mechanism to Export Hydrophobic Drugs. FEBS Letters, 595, 707-716. [Google Scholar] [CrossRef] [PubMed]
[5] Ahmed Juvale, I.I., Abdul Hamid, A.A., Abd Halim, K.B. and Che Has, A.T. (2022) P-Glycoprotein: New Insights into Structure, Physiological Function, Regulation and Alterations in Disease. Heliyon, 8, e09777. [Google Scholar] [CrossRef] [PubMed]
[6] 曾怡馨, 蒋建东, 孔维佳. P-糖蛋白抑制剂研究进展[J]. 中国药理学通报, 2024, 40(12): 2201-2206.
[7] 雷燕, 张建华, 张明, 等. P-糖蛋白抑制剂研究进展[J]. 广州化工, 2016, 44(6): 27-30.
[8] Taha, M.S., Nocera, A., Workman, A., Amiji, M.M. and Bleier, B.S. (2021) P-Glycoprotein Inhibition with Verapamil Overcomes Mometasone Resistance in Chronic Sinusitis with Nasal Polyps. Rhinology journal, 59, 205-211. [Google Scholar] [CrossRef] [PubMed]
[9] Kocharyan, A., Feldman, R., Singleton, A., Han, X. and Bleier, B.S. (2014) P‐Glycoprotein Inhibition Promotes Prednisone Retention in Human Sinonasal Polyp Explants. International Forum of Allergy & Rhinology, 4, 734-738. [Google Scholar] [CrossRef] [PubMed]
[10] Rugo, H.S., Umanzor, G.A., Barrios, F.J., Vasallo, R.H., Chivalan, M.A., Bejarano, S., et al. (2023) Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar versus Intravenous Paclitaxel in Patients with Metastatic Breast Cancer. Journal of Clinical Oncology, 41, 65-74. [Google Scholar] [CrossRef] [PubMed]
[11] Jiang, C., Pan, T., Jiang, Y., Zhang, Z., Zeng, M., Sun, S., et al. (2023) Design and Evaluation of Dibenzoazepine-Tetrahydroisoquinoline Hybrids as Potential P-Glycoprotein Inhibitors against Multidrug Resistant K562/A02 Cells. European Journal of Medicinal Chemistry, 249, Article 115150. [Google Scholar] [CrossRef] [PubMed]
[12] Mollazadeh, S., Sahebkar, A., Kalalinia, F., Behravan, J. and Hadizadeh, F. (2019) Synthesis, in Silico and in Vitro Studies of New 1,4-Dihydropiridine Derivatives for Antitumor and P-Glycoprotein Inhibitory Activity. Bioorganic Chemistry, 91, Article 103156. [Google Scholar] [CrossRef] [PubMed]
[13] Ranjbar, S., Khonkarn, R., Moreno, A., Baubichon-Cortay, H., Miri, R., Khoshneviszadeh, M., et al. (2019) 5-Oxo-hexahydroquinoline Derivatives as Modulators of P-gp, MRP1 and BCRP Transporters to Overcome Multidrug Resistance in Cancer Cells. Toxicology and Applied Pharmacology, 362, 136-149. [Google Scholar] [CrossRef] [PubMed]
[14] Xu, W., Wang, X., Chen, S., Wu, H., Tanaka, S., Onda, K., et al. (2020) Tetrandrine Enhances Glucocorticoid Receptor Translocation Possibly via Inhibition of P-Glycoprotein in Daunorubicin-Resistant Human T Lymphoblastoid Leukemia Cells. European Journal of Pharmacology, 881, Article 173232. [Google Scholar] [CrossRef] [PubMed]
[15] Zhao, P., Li, L., Zhou, S., Qiu, L., Qian, Z., Liu, X., et al. (2018) TPGS Functionalized Mesoporous Silica Nanoparticles for Anticancer Drug Delivery to Overcome Multidrug Resistance. Materials Science and Engineering: C, 84, 108-117. [Google Scholar] [CrossRef] [PubMed]
[16] Mello, F.V.C., de Moraes, G.N., Maia, R.C., Kyeremateng, J., Iram, S.H. and Santos-Oliveira, R. (2020) The Effect of Nanosystems on ATP-Binding Cassette Transporters: Understanding the Influence of Nanosystems on Multidrug Resistance Protein-1 and P-Glycoprotein. International Journal of Molecular Sciences, 21, Article 2630. [Google Scholar] [CrossRef] [PubMed]
[17] Su, Z., Dong, S., Zhao, S., Liu, K., Tan, Y., Jiang, X., et al. (2021) Novel Nanomedicines to Overcome Cancer Multidrug Resistance. Drug Resistance Updates, 58, Article 100777. [Google Scholar] [CrossRef] [PubMed]
[18] Salata, G.C. and Lopes, L.B. (2022) Phosphatidylcholine-Based Nanoemulsions for Paclitaxel and a P-Glycoprotein Inhibitor Delivery and Breast Cancer Intraductal Treatment. Pharmaceuticals, 15, Article 1110. [Google Scholar] [CrossRef] [PubMed]
[19] Cain, D.W. and Cidlowski, J.A. (2017) Immune Regulation by Glucocorticoids. Nature Reviews Immunology, 17, 233-247. [Google Scholar] [CrossRef] [PubMed]
[20] Tavares, L.C.P., Caetano, L.d.V.N. and Ianhez, M. (2024) Side Effects of Chronic Systemic Glucocorticoid Therapy: What Dermatologists Should Know. Anais Brasileiros de Dermatologia, 99, 259-268. [Google Scholar] [CrossRef] [PubMed]
[21] Riggs, D.L., Roberts, P.J., Chirillo, S.C., Cheung-Flynn, J., Prapapanich, V., Ratajczak, T., et al. (2003) The Hsp90-Binding Peptidylprolyl Isomerase FKBP52 Potentiates Glucocorticoid Signaling in Vivo. The EMBO Journal, 22, 1158-1167. [Google Scholar] [CrossRef] [PubMed]
[22] Ratman, D., Vanden Berghe, W., Dejager, L., Libert, C., Tavernier, J., Beck, I.M., et al. (2013) How Glucocorticoid Receptors Modulate the Activity of Other Transcription Factors: A Scope Beyond Tethering. Molecular and Cellular Endocrinology, 380, 41-54. [Google Scholar] [CrossRef] [PubMed]
[23] Vandewalle, J., Luypaert, A., De Bosscher, K. and Libert, C. (2018) Therapeutic Mechanisms of Glucocorticoids. Trends in Endocrinology & Metabolism, 29, 42-54. [Google Scholar] [CrossRef] [PubMed]
[24] Chen, H., Fan, J., Shou, Q., Zhang, L., Ma, H. and Fan, Y. (2015) Hypermethylation of Glucocorticoid Receptor Gene Promoter Results in Glucocorticoid Receptor Gene Low Expression in Peripheral Blood Mononuclear Cells of Patients with Systemic Lupus Erythematosus. Rheumatology International, 35, 1335-1342. [Google Scholar] [CrossRef] [PubMed]
[25] Sousa, A.R., Lane, S.J., Cidlowski, J.A., Staynov, D.Z. and Lee, T.H. (2000) Glucocorticoid Resistance in Asthma Is Associated with Elevated in Vivo Expression of the Glucocorticoid Receptor β-Isoform. Journal of Allergy and Clinical Immunology, 105, 943-950. [Google Scholar] [CrossRef] [PubMed]
[26] Ling, C., Li, Y., Zhu, X., Zhang, C. and Li, M. (2005) Ginsenosides May Reverse the Dexamethasone-Induced Down-Regulation of Glucocorticoid Receptor. General and Comparative Endocrinology, 140, 203-209. [Google Scholar] [CrossRef] [PubMed]
[27] Wilkinson, L., Verhoog, N. and Louw, A. (2018) Novel Role for Receptor Dimerization in Post-Translational Processing and Turnover of the Grα. Scientific Reports, 8, Article No. 14266. [Google Scholar] [CrossRef] [PubMed]
[28] Schäcke, H., Schottelius, A., Döcke, W., Strehlke, P., Jaroch, S., Schmees, N., et al. (2003) Dissociation of Transactivation from Transrepression by a Selective Glucocorticoid Receptor Agonist Leads to Separation of Therapeutic Effects from Side Effects. Proceedings of the National Academy of Sciences, 101, 227-232. [Google Scholar] [CrossRef] [PubMed]
[29] Zhidkova, E.M., Tilova, L.R., Fetisov, T.I., Kirsanov, K.I., Kulikov, E.P., Enikeev, A.D., et al. (2024) Synthesis and Anti-Cancer Activity of the Novel Selective Glucocorticoid Receptor Agonists of the Phenylethanolamine Series. International Journal of Molecular Sciences, 25, Article 8904. [Google Scholar] [CrossRef] [PubMed]
[30] Ripa, L., Edman, K., Dearman, M., Edenro, G., Hendrickx, R., Ullah, V., et al. (2018) Discovery of a Novel Oral Glucocorticoid Receptor Modulator (AZD9567) with Improved Side Effect Profile. Journal of Medicinal Chemistry, 61, 1785-1799. [Google Scholar] [CrossRef] [PubMed]
[31] Ambery, P., Zajac, G., Almquist, J., Prothon, S., Astbury, C., Brown, M.N., et al. (2024) The Effect of AZD9567 vs. Prednisolone on Glycaemic Control in Patients with Type 2 Diabetes Mellitus: Results from a Phase 2a Clinical Trial. British Journal of Clinical Pharmacology, 90, 1921-1931. [Google Scholar] [CrossRef] [PubMed]
[32] Schäcke, H., Zollner, T., Döcke, W., Rehwinkel, H., Jaroch, S., Skuballa, W., et al. (2009) Characterization of ZK 245186, a Novel, Selective Glucocorticoid Receptor Agonist for the Topical Treatment of Inflammatory Skin Diseases. British Journal of Pharmacology, 158, 1088-1103. [Google Scholar] [CrossRef] [PubMed]
[33] Buttgereit, F., Strand, V., Lee, E.B., Simon-Campos, A., McCabe, D., Genet, A., et al. (2019) Fosdagrocorat (PF-04171327) versus Prednisone or Placebo in Rheumatoid Arthritis: A Randomised, Double-Blind, Multicentre, Phase Iib Study. RMD Open, 5, e000889. [Google Scholar] [CrossRef] [PubMed]
[34] Kurimoto, T., Tamai, I., Nakagawa, T., Miyai, A., Yamamoto, Y., Kosugi, Y., et al. (2021) JTP-117968, a Novel Selective Glucocorticoid Receptor Modulator, Exhibits Significant Anti-Inflammatory Effect While Maintaining Bone Mineral Density in Mice. European Journal of Pharmacology, 895, Article 173880. [Google Scholar] [CrossRef] [PubMed]
[35] Jakob, F., Hennen, S., Gautrois, M., Khalil, F. and Lockhart, A. (2025) Novel Selective Glucocorticoid Receptor Modulator GRM-01 Demonstrates Dissociation of Anti-Inflammatory Effects from Adverse Effects on Glucose and Bone Metabolism. Frontiers in Pharmacology, 16, Article ID: 1542351. [Google Scholar] [CrossRef] [PubMed]
[36] Hu, X., Pang, J., Chen, C., Jiang, D., Shen, C., Chai, X., et al. (2022) Discovery of Novel Non-Steroidal Selective Glucocorticoid Receptor Modulators by Structure-And IGN-Based Virtual Screening, Structural Optimization, and Biological Evaluation. European Journal of Medicinal Chemistry, 237, Article 114382. [Google Scholar] [CrossRef] [PubMed]
[37] Hu, X., Pang, J., Zhang, J., Shen, C., Chai, X., Wang, E., et al. (2022) Discovery of Novel GR Ligands toward Druggable GR Antagonist Conformations Identified by MD Simulations and Markov State Model Analysis. Advanced Science, 9, e2102435. [Google Scholar] [CrossRef] [PubMed]
[38] Smith, E.C., Conklin, L.S., Hoffman, E.P., Clemens, P.R., Mah, J.K., Finkel, R.S., et al. (2020) Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: An 18-Month Interim Analysis of a Non-Randomized Open-Label Extension Study. PLOS Medicine, 17, e1003222. [Google Scholar] [CrossRef] [PubMed]
[39] Keam, S.J. (2023) Vamorolone: First Approval. Drugs, 84, 111-117. [Google Scholar] [CrossRef] [PubMed]
[40] Livingstone, D.E.W., Sooy, K., Sykes, C., Webster, S.P., Walker, B.R. and Andrew, R. (2023) 5α‐Tetrahydrocorticosterone: A Topical Anti‐Inflammatory Glucocorticoid with an Improved Therapeutic Index in a Murine Model of Dermatitis. British Journal of Pharmacology, 181, 1256-1267. [Google Scholar] [CrossRef] [PubMed]
[41] Yang, C., Nixon, M., Kenyon, C., Livingstone, D., Duffin, R., Rossi, A., et al. (2011) 5α‐Reduced Glucocorticoids Exhibit Dissociated Anti‐Inflammatory and Metabolic Effects. British Journal of Pharmacology, 164, 1661-1671. [Google Scholar] [CrossRef] [PubMed]
[42] Louw, A. (2019) GR Dimerization and the Impact of GR Dimerization on GR Protein Stability and Half-Life. Frontiers in Immunology, 10, Article ID: 1693. [Google Scholar] [CrossRef] [PubMed]
[43] Souffriau, J., Eggermont, M., Van Ryckeghem, S., Van Looveren, K., Van Wyngene, L., Van Hamme, E., et al. (2018) A Screening Assay for Selective Dimerizing Glucocorticoid Receptor Agonists and Modulators (SEDIGRAM) That Are Effective against Acute Inflammation. Scientific Reports, 8, Article No. 12894. [Google Scholar] [CrossRef] [PubMed]
[44] Timmermans, S., Vandewalle, J. and Libert, C. (2022) Dimerization of the Glucocorticoid Receptor and Its Importance in (Patho)physiology: A Primer. Cells, 11, Article 683. [Google Scholar] [CrossRef] [PubMed]
[45] 师哲, 李勇. 人参皂苷对糖皮质激素受体途径调节作用研究进展[J]. 中华中医药学刊, 2021, 39(11): 162-165.
[46] Li, J., Huang, Y., Luo, Q., Luo, X., Xu, J., Ye, W., et al. (2025) Dehydrotumulosic Acid: A Potential Glucocorticoid Receptor Agonist with Anti-Coxsackievirus Activity. Phytomedicine, 146, Article 157107. [Google Scholar] [CrossRef] [PubMed]
[47] Weaver, I.C.G. (2009) Epigenetic Effects of Glucocorticoids. Seminars in Fetal and Neonatal Medicine, 14, 143-150. [Google Scholar] [CrossRef] [PubMed]
[48] Ito, K., Yamamura, S., Essilfie-Quaye, S., Cosio, B., Ito, M., Barnes, P.J., et al. (2005) Histone Deacetylase 2-Mediated Deacetylation of the Glucocorticoid Receptor Enables NF-κB Suppression. The Journal of Experimental Medicine, 203, 7-13. [Google Scholar] [CrossRef] [PubMed]
[49] Tao, F., Zhou, Y., Wang, M., Wang, C., Zhu, W., Han, Z., et al. (2022) Metformin Alleviates Chronic Obstructive Pulmonary Disease and Cigarette Smoke Extract-Induced Glucocorticoid Resistance by Activating the Nuclear Factor E2-Related Factor 2/Heme Oxygenase-1 Signaling Pathway. The Korean Journal of Physiology & Pharmacology, 26, 95-111. [Google Scholar] [CrossRef] [PubMed]
[50] Li, J., Zhu, X., Ye, S., Dong, Q., Hou, J., Liu, J., et al. (2024) Tanshinone IIA Potentiates the Therapeutic Efficacy of Glucocorticoids in Lipopolysaccharide-Treated HEI-OC1 Cells through Modulation of the FOXP3/NRF2 Signaling Pathway. Acta Biochimica et Biophysica Sinica, 57, 727-737. [Google Scholar] [CrossRef] [PubMed]
[51] 梁静, 颜丽. 大环内酯类抗生素联用吸入类固醇治疗哮喘的临床研究[J]. 中国实用医药, 2016, 11(29): 130-131.
[52] 张杰民. 小剂量阿奇霉素联合吸入性糖皮质激素治疗慢性阻塞性肺疾病60例分析[J]. 广州医药, 2009, 40(3): 26-28.
[53] Sun, X., Li, Z., Zhang, Y., Zhou, G., Zhang, J., Deng, J., et al. (2015) Combination of Erythromycin and Dexamethasone Improves Corticosteroid Sensitivity Induced by CSE through Inhibiting PI3K-δ/Akt Pathway and Increasing GR Expression. American Journal of Physiology-Lung Cellular and Molecular Physiology, 309, L139-L146. [Google Scholar] [CrossRef] [PubMed]
[54] Zhou, Q., Dai, Y., Du, X., Hou, J., Qi, H. and She, W. (2017) Aminophylline Restores Glucocorticoid Sensitivity in a Guinea Pig Model of Sudden Sensorineural Hearing Loss Induced by Lipopolysaccharide. Scientific Reports, 7, Article No. 2736. [Google Scholar] [CrossRef] [PubMed]

为你推荐